Anika Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Anika Therapeutics has a total shareholder equity of $179.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $231.4M and $51.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$62.37m |
| Equity | US$179.86m |
| Total liabilities | US$51.54m |
| Total assets | US$231.41m |
Recent financial health updates
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth
Aug 03
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly
Feb 09Recent updates
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet
Dec 19Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?
Jan 30Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth
Aug 03Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity
Mar 11Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?
Jun 25Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow
May 28Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?
Mar 16Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly
Feb 09An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued
Jan 13If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%
Dec 18
Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Financial Position Analysis
Short Term Liabilities: ANIK's short term assets ($136.1M) exceed its short term liabilities ($25.5M).
Long Term Liabilities: ANIK's short term assets ($136.1M) exceed its long term liabilities ($26.0M).
Debt to Equity History and Analysis
Debt Level: ANIK is debt free.
Reducing Debt: ANIK had no debt 5 years ago.
Debt Coverage: ANIK has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ANIK has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 20:07 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anika Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Mark Landy | Northland Capital Markets |
| James Sidoti | Sidoti & Company, LLC |